350 related articles for article (PubMed ID: 30293765)
1. Cost-effectiveness analysis of maternal immunisation against group B Streptococcus (GBS) disease: A modelling study.
Giorgakoudi K; O'Sullivan C; Heath PT; Ladhani S; Lamagni T; Ramsay M; Al-Janabi H; Trotter C
Vaccine; 2018 Nov; 36(46):7033-7042. PubMed ID: 30293765
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of a potential group B streptococcal vaccine for pregnant women in the United States.
Kim SY; Nguyen C; Russell LB; Tomczyk S; Abdul-Hakeem F; Schrag SJ; Verani JR; Sinha A
Vaccine; 2017 Oct; 35(45):6238-6247. PubMed ID: 28951085
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of a potential group B streptococcal vaccine program for pregnant women in South Africa.
Kim SY; Russell LB; Park J; Verani JR; Madhi SA; Cutland CL; Schrag SJ; Sinha A
Vaccine; 2014 Apr; 32(17):1954-63. PubMed ID: 24530145
[TBL] [Abstract][Full Text] [Related]
4. Prevention of group B streptococcal disease in the first 3 months of life: would routine maternal immunization during pregnancy be cost-effective?
Oster G; Edelsberg J; Hennegan K; Lewin C; Narasimhan V; Slobod K; Edwards MS; Baker CJ
Vaccine; 2014 Aug; 32(37):4778-85. PubMed ID: 24992717
[TBL] [Abstract][Full Text] [Related]
5. Group B Streptococcus: Trials and Tribulations.
Davies HG; Carreras-Abad C; Le Doare K; Heath PT
Pediatr Infect Dis J; 2019 Jun; 38(6S Suppl 1):S72-S76. PubMed ID: 31205250
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of maternal immunization against neonatal invasive Group B Streptococcus in the Netherlands.
Hahn BA; de Gier B; van Kassel MN; Bijlsma MW; van Leeuwen E; Wouters MGAJ; van der Ende A; van de Beek D; Wallinga J; Hahné SJM; Jan van Hoek A
Vaccine; 2021 May; 39(21):2876-2885. PubMed ID: 33895018
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of maternal GBS immunization in low-income sub-Saharan Africa.
Russell LB; Kim SY; Cosgriff B; Pentakota SR; Schrag SJ; Sobanjo-Ter Meulen A; Verani JR; Sinha A
Vaccine; 2017 Dec; 35(49 Pt B):6905-6914. PubMed ID: 29129451
[TBL] [Abstract][Full Text] [Related]
8. Maternal immunisation against Group B Streptococcus: A global analysis of health impact and cost-effectiveness.
Procter SR; Gonçalves BP; Paul P; Chandna J; Seedat F; Koukounari A; Hutubessy R; Trotter C; Lawn JE; Jit M
PLoS Med; 2023 Mar; 20(3):e1004068. PubMed ID: 36917564
[TBL] [Abstract][Full Text] [Related]
9. Potential cost-effectiveness of a maternal Group B streptococcal vaccine in The Gambia.
Ahmed N; Giorgakoudi K; Usuf E; Okomo U; Clarke E; Kampmann B; Le Doare K; Trotter C
Vaccine; 2020 Mar; 38(15):3096-3104. PubMed ID: 32147298
[TBL] [Abstract][Full Text] [Related]
10. Prospects for preventing infant invasive GBS disease through maternal vaccination.
Madhi SA; Dangor Z
Vaccine; 2017 Aug; 35(35 Pt A):4457-4460. PubMed ID: 28237500
[TBL] [Abstract][Full Text] [Related]
11. Intrapartum antibiotic prophylaxis for the prevention of perinatal group B streptococcal disease: experience in the United States and implications for a potential group B streptococcal vaccine.
Schrag SJ; Verani JR
Vaccine; 2013 Aug; 31 Suppl 4():D20-6. PubMed ID: 23219695
[TBL] [Abstract][Full Text] [Related]
12. Developing a serocorrelate of protection against invasive group B streptococcus disease in pregnant women: a feasibility study.
Carreras-Abad C; Cochet M; Hall T; Ramkhelawon L; Khalil A; Peregrine E; Vinayakarao L; Sivarajan S; Hamid R; Planche T; Sheridan E; Winchester S; Plumb J; Djennad A; Andrews N; Le Doare K; Heath P
Health Technol Assess; 2019 Dec; 23(67):1-40. PubMed ID: 31855555
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of maternal vaccination against Group B streptococcus in Japan.
Sorano S; Procter SR; Seale AC
Vaccine X; 2023 Aug; 14():100332. PubMed ID: 37441365
[TBL] [Abstract][Full Text] [Related]
14. Disease burden of neonatal invasive Group B Streptococcus infection in the Netherlands.
de Gier B; van Kassel MN; Sanders EAM; van de Beek D; Hahné SJM; van der Ende A; Bijlsma MW
PLoS One; 2019; 14(5):e0216749. PubMed ID: 31071191
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial.
Madhi SA; Cutland CL; Jose L; Koen A; Govender N; Wittke F; Olugbosi M; Meulen AS; Baker S; Dull PM; Narasimhan V; Slobod K
Lancet Infect Dis; 2016 Aug; 16(8):923-34. PubMed ID: 27139805
[TBL] [Abstract][Full Text] [Related]
16. The projected health benefits of maternal group B streptococcal vaccination in the era of chemoprophylaxis.
Sinha A; Lieu TA; Paoletti LC; Weinstein MC; Platt R
Vaccine; 2005 May; 23(24):3187-95. PubMed ID: 15837219
[TBL] [Abstract][Full Text] [Related]
17. Comparison of prevention strategies for neonatal group B streptococcal infection. A population-based economic analysis.
Mohle-Boetani JC; Schuchat A; Plikaytis BD; Smith JD; Broome CV
JAMA; 1993 Sep 22-29; 270(12):1442-8. PubMed ID: 8371444
[TBL] [Abstract][Full Text] [Related]
18. Estimates of the Burden of Group B Streptococcal Disease Worldwide for Pregnant Women, Stillbirths, and Children.
Seale AC; Bianchi-Jassir F; Russell NJ; Kohli-Lynch M; Tann CJ; Hall J; Madrid L; Blencowe H; Cousens S; Baker CJ; Bartlett L; Cutland C; Gravett MG; Heath PT; Ip M; Le Doare K; Madhi SA; Rubens CE; Saha SK; Schrag SJ; Sobanjo-Ter Meulen A; Vekemans J; Lawn JE
Clin Infect Dis; 2017 Nov; 65(suppl_2):S200-S219. PubMed ID: 29117332
[TBL] [Abstract][Full Text] [Related]
19. Early-onset group B streptococcal disease in the era of maternal screening.
Puopolo KM; Madoff LC; Eichenwald EC
Pediatrics; 2005 May; 115(5):1240-6. PubMed ID: 15867030
[TBL] [Abstract][Full Text] [Related]
20. Aetiology of neonatal sepsis in Nigeria, and relevance of Group b streptococcus: A systematic review.
Medugu N; Iregbu K; Iroh Tam PY; Obaro S
PLoS One; 2018; 13(7):e0200350. PubMed ID: 30016358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
